Search research articles
Contact Us
Filters
Showing results (41-50 of 172) with videos related to
Page
of 18
Sort By:
Clinical Pharmacology and Therapeutics
|
July 17, 2007
Current assessment of risk-benefit by regulators: is it time to introduce decision analyses?
D A Hughes, A M Bayoumi, M Pirmohamed
Clinical Pharmacology and Therapeutics
|
February 28, 2013
Response to "HLA allelic variants and carbamazepine-induced hypersensitivity"
V L M Yip, M Pirmohamed, A Alfirevic
Drug Safety
|
August 1, 1994
The role of active metabolites in drug toxicity
M Pirmohamed, N R Kitteringham, B K Park
Lancet (London, England)
|
April 10, 1993
Interaction of metoprolol and fluoxetine
T Walley, M Pirmohamed, C Proudlove, et al.
Clinical Pharmacology and Therapeutics
|
September 27, 2013
Cost-effectiveness of pharmacogenetics-guided warfarin therapy vs. alternative anticoagulation in atrial fibrillation
J Pink, M Pirmohamed, S Lane, et al.
The Pharmacogenomics Journal
|
July 8, 2009
Investigation of inter-individual variability of the one-carbon folate pathway: a bioinformatic and genetic review
D F Carr, G Whiteley, A Alfirevic, et al.
Postgraduate Medical Journal
|
October 26, 1999
Haemolytic anaemia associated with indinavir
S Morrison-Griffiths, M Newman, C O'Mahony, et al.
Neurology
|
April 11, 2001
TNFalpha promoter region gene polymorphisms in carbamazepine-hypersensitive patients
M Pirmohamed, K Lin, D Chadwick, et al.
Clinical Pharmacology and Therapeutics
|
April 15, 2015
Pharmacogenetic Markers of Drug Efficacy and Toxicity
V L M Yip, D B Hawcutt, M Pirmohamed
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology
|
April 25, 2016
The role of Clostridium difficile in the paediatric and neonatal gut - a narrative review
E A Lees, F Miyajima, M Pirmohamed, et al.
Page
of 18
Search research articles
Search
Showing results (41-50 of 172) with videos related to
Sort By:
Page
of 18
Clinical Pharmacology and Therapeutics
|
July 17, 2007
Current assessment of risk-benefit by regulators: is it time to introduce decision analyses?
D A Hughes, A M Bayoumi, M Pirmohamed
Clinical Pharmacology and Therapeutics
|
February 28, 2013
Response to "HLA allelic variants and carbamazepine-induced hypersensitivity"
V L M Yip, M Pirmohamed, A Alfirevic
Drug Safety
|
August 1, 1994
The role of active metabolites in drug toxicity
M Pirmohamed, N R Kitteringham, B K Park
Lancet (London, England)
|
April 10, 1993
Interaction of metoprolol and fluoxetine
T Walley, M Pirmohamed, C Proudlove, et al.
Clinical Pharmacology and Therapeutics
|
September 27, 2013
Cost-effectiveness of pharmacogenetics-guided warfarin therapy vs. alternative anticoagulation in atrial fibrillation
J Pink, M Pirmohamed, S Lane, et al.
The Pharmacogenomics Journal
|
July 8, 2009
Investigation of inter-individual variability of the one-carbon folate pathway: a bioinformatic and genetic review
D F Carr, G Whiteley, A Alfirevic, et al.
Postgraduate Medical Journal
|
October 26, 1999
Haemolytic anaemia associated with indinavir
S Morrison-Griffiths, M Newman, C O'Mahony, et al.
Neurology
|
April 11, 2001
TNFalpha promoter region gene polymorphisms in carbamazepine-hypersensitive patients
M Pirmohamed, K Lin, D Chadwick, et al.
Clinical Pharmacology and Therapeutics
|
April 15, 2015
Pharmacogenetic Markers of Drug Efficacy and Toxicity
V L M Yip, D B Hawcutt, M Pirmohamed
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology
|
April 25, 2016
The role of Clostridium difficile in the paediatric and neonatal gut - a narrative review
E A Lees, F Miyajima, M Pirmohamed, et al.
Page
of 18